Sign inJoin waitlistJoin the waitlist

Sneha Ramakrishna

Principal · Stanford Health Care

Credentials: · · · · ·

History

Stanford Health Care
Present
Stanford Health Care
Present

Center for Cancer Research
2015–2016
Pediatrics
Children's Hospital of Philadelphia
2012–2015
Case Western Reserve University School of Medicine
2008–2012

Research

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Nature Medicine · 2018 · 1,135 citations
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Nature · 2022 · Co-first of 47 authors · 697 citations
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Nature Medicine · 2021 · 534 citations

Kara Davis
19 papers · 8 as a resident
Liora Schultz
17 papers
Crystal Mackall
16 papers
TB
Tina Baggott
9 papers
Robbie Majzner
8 papers
JM
Jen Moon
6 papers
AJ
Ashley Jacobs
5 papers
CC
Cynthia Campen
5 papers
Jasia Mahdi
5 papers · 4 as a fellow
Lori Muffly
5 papers
Matthew Frank
5 papers
Michelle Monje
5 papers

Grants

Defining Pre-Treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
National Cancer Institute · K08
Contact PI · $1.1M · Stanford University
2022–2027

Clinical trials

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Principal investigator · Recruiting · Phase 1
Stanford University
2024–2029
SPEARHEAD-3 Pediatric Study
Site PI · Recruiting · Phase 1, Phase 2
USWM CT, LLC
2023–2038
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Sub-investigator · Recruiting · Phase 1
Stanford University
2022–2027
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
Sub-investigator · Recruiting · Phase 1
Stanford University
2020–2043